Home>>Signaling Pathways>> Cardiovascular>> Vasoconstriction>>Levonordefrin

Levonordefrin (Synonyms: Corbadrine, (–)-α-methyl Noradrenaline, (–)-3,4-dihydroxy Norephedrine)

Catalog No.GC40807

Levonordefrin is the (-)-enantiomer of nordefrin, a synthetic derivative of norepinephrine, that acts as a vasoconstrictor.

Products are for research use only. Not for human use. We do not sell to patients.

Levonordefrin Chemical Structure

Cas No.: 829-74-3

Size Price Stock Qty
10mg
$83.00
In stock
50mg
$251.00
In stock
100mg
$462.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Levonordefrin is the (-)-enantiomer of nordefrin, a synthetic derivative of norepinephrine , that acts as a vasoconstrictor. Levonordefrin (1-5 µg/kg) rapidly increases blood pressure and heart rate in anesthetized dogs and has a more potent effect on blood pressure than the dextronordefrin enantiomer. It also inhibits carbamylcholine-induced uterine contractions in isolated rat uterine strips (EC50 = 0.0032 µg/ml). Levonordefrin (0.514 and 1.542 mg/kg), in combination with mepivacaine and administered via intraoral infiltration, increases systolic arterial blood pressure in anesthetized dogs, however, the effect is not dose-dependent and the increase is not greater than 5.33%. Formulations containing levonordefrin have been used in combination with local anesthetics in dentistry to prolong anesthetic effects.

Reviews

Review for Levonordefrin

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Levonordefrin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.